Special Issue

Personalized Diagnosis and Therapy for Multiple Sclerosis

Message from the Guest Editor

Current management of multiple sclerosis (MS) takes advantage of the many disease-modifying therapeutics of anti-inflammatory and immunomodulatory nature, but people with MS need to be cared for in a new and personalized profound way. We need to evaluate clinical and subclinical changes with greater accuracy through more precise imaging and molecular biomarkers. Advance therapies such as cell therapy, mRNA vaccine technology and regenerative medicine are a way to provide therapeutic solutions. A personalized immunogram would help us to determine whether a treatment will have optimal results and be the best way to predict the response of immunotherapy in the patient. Large datasets and MS registries generated in a real-world setting will allow a joint analysis of very large sets of structured data, improving the life of people with MS.
Background: People with MS need to be cared for in a new and personalized profound way.
Aim and scope: Increase diagnostic sensitivity, augment detection, improve treatment and patient care.
What kind of paper are we looking for? A paper that mobilizes the creation of these new ideas and solutions.

Guest Editor

Dr. Cristina M. Ramo-Tello
Multiple Sclerosis Unit, Department of Neurosciences, Germans Trias i Pujol Hospital, Badalona 08916, Badalona, Spain

Deadline for manuscript submissions

closed (10 November 2021)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/80759

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

MDPI

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).

MDPI